Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience (SKYE) is a clinical-stage biopharmaceutical innovator developing targeted therapies through cannabinoid receptor modulation. This page serves as the definitive source for verified company announcements, research milestones, and financial updates.
Investors and researchers will find timely updates on clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes earnings reports, pipeline progress for nimacimab (peripheral CB1 inhibitor), and scientific presentations - all organized for efficient due diligence.
Key focus areas include metabolic disorder therapeutics, antibody-based drug development, and clinical safety data. Content is rigorously verified to ensure compliance with financial disclosure standards while maintaining accessibility for both specialist and general audiences.
Bookmark this page for structured access to SKYE's evolving position in biopharmaceutical innovation, with particular emphasis on obesity treatment research and peripheral endocannabinoid system modulation.
Skye Bioscience (OTCQB: SKYE) announced the completion of SBI-100 Ophthalmic Emulsion production for its Phase 1 clinical trial, which focuses on treating glaucoma. The final product is expected to be clinically available in October, pending quality testing results. Clinical site initiation will occur in mid-October, followed by patient dosing starting in November. SBI-100 OE aims to effectively lower intraocular pressure (IOP) using a novel synthetic cannabinoid formulation, potentially offering a new treatment class for glaucoma, a leading cause of irreversible blindness.
Skye Bioscience, Inc. (OTCQB: SKYE) announced the filing of its definitive proxy statement ahead of a special meeting on September 30, 2022. This meeting will address a proposed business combination with Emerald Health Therapeutics, Inc. Stockholders as of August 29, 2022, will receive voting materials via mail or email. CEO Punit Dhillon expressed gratitude for Emerald's support and emphasized the importance of stockholder voting to secure valuable resources for their business plan. The definitive proxy statement is available for viewing online.
Skye Bioscience (OTCQB: SKYE) announces that 87.07% of Emerald Health Therapeutics shareholders approved the proposed merger plan. The next step involves Skye seeking shareholder approval in an upcoming meeting. Regulatory approval for Skye's Phase 1 clinical study has been granted, with enrollment expected to complete by early 2023. The company plans to submit its Investigational New Drug application to the FDA by year-end 2022 for a Phase II study on SBI-100 targeting glaucoma, a condition affecting over 70 million people worldwide.
